IQVIATM, a healthcare research firm (www.iqvia.com), is currently conducting an interview study. This study is sponsored by a pharmaceutical company that is working on developing a new treatment for Lupus. The purpose of this research is to learn about how people with severe Lupus think and feel about a treatment known as chimeric antigen receptor cell therapy, or CAR-T cell therapy for short. We do not expect you to know about this treatment prior to the interview. Any information you need to comment on the therapy will be provided to you during the interview. Your answers will be used to try to reduce burden for patients who receive therapies like CAR-T cell therapy and to improve the overall experience of receiving treatment for Lupus. We will be asking you some questions to see if you are eligible to participate. If we find that you meet the criteria to participate in this study, you may be asked to take part in a telephone interview.
Any information you provide to us as part of the eligibility questions will be treated as confidential. It will be combined with feedback from others like yourself and will be stored in a secure server. This means your information will be kept secure at all times. Personally identifying information, such as names and locations, will be removed from your data and your information will not be passed to any other organization without your permission. Any personally identifying information you give to us as part of the eligibility questions will be destroyed after five years for named data and 15 years for masked data after study completion.
If you are eligible to take part in this interview study, you will be provided with a consent form, which explains how the study works and your rights as a study participant.
You have the right to withdraw from this study at any time. For more information about your rights, please see our privacy notice, which is available at www.iqvia.com/about-us/privacy.